Amani Asnacios

1.0k total citations
14 papers, 726 citations indexed

About

Amani Asnacios is a scholar working on Oncology, Epidemiology and Hepatology. According to data from OpenAlex, Amani Asnacios has authored 14 papers receiving a total of 726 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Oncology, 5 papers in Epidemiology and 5 papers in Hepatology. Recurrent topics in Amani Asnacios's work include Pancreatic and Hepatic Oncology Research (4 papers), Colorectal Cancer Treatments and Studies (4 papers) and Neuroendocrine Tumor Research Advances (3 papers). Amani Asnacios is often cited by papers focused on Pancreatic and Hepatic Oncology Research (4 papers), Colorectal Cancer Treatments and Studies (4 papers) and Neuroendocrine Tumor Research Advances (3 papers). Amani Asnacios collaborates with scholars based in France, Belgium and Germany. Amani Asnacios's co-authors include Thierry Poynard, Julien Taı̈eb, Sylvie Naveau, Gabriel Perlemuter, Touraj Mansourbakht, Micheline Njiké‐Nakseu, Sophie Prévôt, Pascal Artru, Axel Balian and L Hannoun and has published in prestigious journals such as Journal of Clinical Oncology, Gastroenterology and Hepatology.

In The Last Decade

Amani Asnacios

14 papers receiving 702 citations

Peers

Countries citing papers authored by Amani Asnacios

Since Specialization

Citations

This map shows the geographic impact of Amani Asnacios's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Amani Asnacios with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Amani Asnacios more than expected).

Fields of papers citing papers by Amani Asnacios

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Amani Asnacios. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Amani Asnacios. The network helps show where Amani Asnacios may publish in the future.

Co-authorship network of co-authors of Amani Asnacios

This figure shows the co-authorship network connecting the top 25 collaborators of Amani Asnacios. A scholar is included among the top collaborators of Amani Asnacios based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Amani Asnacios. Amani Asnacios is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

14 of 14 papers shown

#	Work	Indexed citations
1	Fixed-dose rate gemcitabine alone or alternating with FOLFIRI.3 (irinotecan, leucovorin and fluorouracil) in the first-line treatment of patients with metastatic pancreatic adenocarcinoma: An AGEO randomised phase II study (FIRGEM) 2014 ·European Journal of Cancer ·Isabelle Trouilloud, (unknown), David Malka, Pascal Artru, Mélanie Gauthier, Thierry Lecomte, Thomas Aparicio, Anne Thirot‐Bidault, (unknown), Amani Asnacios, (unknown), Francine Fein, Olivier Dubreuil, Bruno Landi, Aziz Zaanan, Franck Bonnetain, Julien Taı̈eb	26
2	FOLFIRI.3 (CPT-11 plus folinic acid plus 5-FU) alternating with gemcitabine or gemcitabine (G) alone in patients (pts) with previously untreated metastatic pancreatic adenocarcinoma (MPA): Results of the randomized multicenter AGEO phase II trial FIRGEM. 2012 ·Journal of Clinical Oncology ·Isabelle Trouilloud, (unknown), Pascal Artru, Thierry Lecomte, Mélanie Gauthier, Thomas Aparicio, Anne Thirot‐Bidault, David Malka, (unknown), Amani Asnacios, (unknown), Francine Fein, (unknown), Olivier Dubreuil, Lysiane Marthey, Aziz Zaanan, Franck Bonnetain, Julien Taı̈eb	9
3	Body Fat Distribution and Risk Factors for Fibrosis in Patients with Alcoholic Liver Disease 2012 ·Alcoholism Clinical and Experimental Research ·Sylvie Naveau, (unknown), Axel Balian, Micheline Njiké‐Nakseu, (unknown), Amani Asnacios, Sophie Prévôt, Gabriel Perlemuter	21
4	Gastrointestinal toxicities of novel agents in cancer therapy 2009 ·European Journal of Cancer ·Amani Asnacios, Sylvie Naveau, Gabriel Perlemuter	22
5	Gemcitabine plus oxaliplatin (GEMOX) combined with cetuximab in patients with progressive advanced stage hepatocellular carcinoma 2008 ·Cancer ·Amani Asnacios, Lætitia Fartoux, Olivier Romano, (unknown), (unknown), (unknown), Pascal Artru, Thierry Poynard, Olivier Rosmorduc, Mohamed Hebbar, Julien Taı̈eb	109
6	Indium-111–Pentetreotide Scintigraphy and Somatostatin Receptor Subtype 2 Expression: New Prognostic Factors for Malignant Well-Differentiated Endocrine Tumors 2008 ·Journal of Clinical Oncology ·Amani Asnacios, F. Courbon, Philippe Rochaix, (unknown), (unknown), Christiane Susini, Stefan Schulz, A Boneu, Rosine Guimbaud, Louis Buscail	83
7	Diagnostic and prognostic values of noninvasive biomarkers of fibrosis in patients with alcoholic liver disease† 2008 ·Hepatology ·Sylvie Naveau, (unknown), Amani Asnacios, Hélène Agostini, Annie Abella, Nadège Barri‐Ova, Barbara Dauvois, Sophie Prévôt, Yen Ngo, M. Munteanu, Axel Balian, Micheline Njiké‐Nakseu, Gabriel Perlemuter, Thierry Poynard	202
8	Gemcitabine plus oxaliplatin (GEMOX) in patients with advanced hepatocellular carcinoma (HCC) 2007 ·Cancer ·Samy Louafi, Valérie Boige, Michel Ducreux, Luminita Bonyhay, Touraj Mansourbakht, Thierry de Baère, Amani Asnacios, L Hannoun, Thierry Poynard, Julien Taı̈eb	145
9	Gemcitabine, oxaliplatin (GEMOX) and cetuximab for treatment of hepatocellular carcinoma (HCC): Results of the phase II study ERGO 2007 ·Journal of Clinical Oncology ·(unknown), Mohamed Hebbar, Olivier Rosmorduc, (unknown), Amani Asnacios, (unknown), Lætitia Fartoux, Pascal Artru, Thierry Poynard, Julien Taı̈eb	18
10	FOLFIRI.3, a new regimen combining 5-fluorouracil, folinic acid and irinotecan, for advanced pancreatic cancer: results of an Association des Gastro-Entérologues Oncologues (Gastroenterologist Oncologist Association) multicenter phase II study 2006 ·Annals of Oncology ·Julien Taı̈eb, Thierry Lecomte, Thomas Aparicio, Amani Asnacios, Touraj Mansourbakht, Pascal Artru, David Fallik, Jean‐Philippe Spano, B. Landi, Gérard Lledo, Jérôme Desrame	40
11	Characterization of the Bystander Effect of Somatostatin Receptor sst2 After In Vivo Gene Transfer into Human Pancreatic Cancer Cells 2005 ·Human Gene Therapy ·Nicolas Carrère, Fabienne Vernejoul, Anny Souque, Amani Asnacios, Nicole Vaysse, Lucien Pradayrol, Christiane Susini, Louis Buscail, Pierre Cordelier	3
12	Characterization of the Bystander Effect of Somatostatin Receptor sst2 After In Vivo Gene Transfer into Human Pancreatic Cancer Cells 2005 ·Human Gene Therapy ·Nicolas Carrère, Fabienne Vernejoul, Anny Souque, Amani Asnacios, Nicole Vaysse, Lucien Pradayrol, Christiane Susini, Louis Buscail, Pierre Cordelier	29
13	Treatment of murine hepatocellular carcinoma using genetically modified cells to express interleukin‐12 2004 ·Journal of Gastroenterology and Hepatology ·Jean‐Marie Péron, Bettina Couderc, Philippe Rochaix, Victorine Douin‐Echinard, Amani Asnacios, Anny Souque, Jean‐Jacques Voigt, Louis Buscail, (unknown), Gilles Favre	18
14	Predictive diagnostic value of endoscopic ultrasound-guided fine needle aspiration of unilocular macrocystic lesions of the pancreas 2003 ·Gastroenterology ·Amani Asnacios, Louis Buscail, Janick Sèlves, (unknown), G Fourtanier, Bertrand Suc, B. Pradère, Jacques Frexinos, J Escourrou	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact